TNIK Inhibition Has Dual Synergistic Effects on Tumor and Associated Immune Cells
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Treatment with checkpoint inhibitors can be extraordinarily effective in a fraction of patients, particularly those whose tumors are pre‐infiltrated by T cells. In others, efficacy is considerably lower, which has led to interest in developing strategies for sensitization to immunotherapy. Using various colorectal cancer mouse models, it is shown that the use of Traf2 and Nck‐interacting protein kinase inhibitors (TNIKi) unexpectedly increases tumor infiltration by PD‐1+ CD8+ T cells, thus contributing to tumor control. This appears to happen by two independent mechanisms, by inducing immunogenic cell death and separately by directly activating CD8. The use of TNIKi achieves complete tumor control in 50% of mice when combined with checkpoint inhibitor targeting PD‐1. These findings reveal immunogenic properties of TNIKi and indicate that the proportion of colorectal cancers responding to checkpoint therapy can be increased by combining it with immunogenic kinase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The TNIK inhibitor NCB0846 as well as the FDA-approved mebendazole that targets TNIK display promising activity in preclinical CRC models demonstrating the therapeutic potential of Wnt-pathway targeting for CRC treatment [111].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [111]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M., & Wallace, M. B. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32319-0 · Cited by 4,974
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Efficient subpixel image registration algorithms
Guizar-Sicairos, M., Thurman, S. T., & Fienup, J. R. (2008) · Optics Letters · doi:10.1364/ol.33.000156 · Cited by 1,905
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Cited by
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“The TNIK inhibitor NCB0846 as well as the FDA-approved mebendazole that targets TNIK display promising activity in preclinical CRC models demonstrating the therapeutic potential of Wnt-pathway targeting for CRC treatment [111].”
BackgroundElkrief, A., Montesion, M., Sivakumar, S., Hale, C. R., Bowman, A. S., Bektaş, A. B., Bradić, M., Kang, W., Chan, E., Gogia, P., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01488 · Cited by 46
TNIK’s emerging role in cancer, metabolism, and age-related diseases
Ewald, C. Y., Pulous, F. E., Lok, S. W. Y., Pun, F. W., Aliper, A., Ren, F., & Zhavoronkov, A. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.04.010 · Cited by 27
Aladinskiy, V., Kruse, C. G., Qin, L., Babin, E., Fan, Y., Andreev, G., Zhao, H., Fu, Y., Zhang, M., Ivanenkov, Y. A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01580 · Cited by 21
MAP4K signaling pathways in cancer: roles, mechanisms and therapeutic opportunities
Bunardi, C. S., Yeom, M., Kosasih, P., Han, H., Wang, W., & Seo, G. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01544-8 · Cited by 17
Metadata
- Authors
- Kim, J., Oh, J., Peterson, H. M., Carlson, J. C. T., Pittet, M. J., & Weissleder, R.
- Affiliations
- Massachusetts General Hospital (US)
- Harvard University (US)
- Center for Systems Biology Massachusetts General Hospital 185 Cambridge St, CPZN 5206 Boston MA 02114 USA
- Corresponding author
- Weissleder, Ralph
- Venue
- Advanced Biology
- Publisher
- Wiley
- Published
- 2022-06-08
- Volume
- 6
- Issue
- 8
- Pages
- e2200030-e2200030
- ISSN
- 2701-0198 (ISSN-L)
- PMC
- PMC9398996
- OpenAlex
- W4281735166
- Cited by
- 14
- References
- 43
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 6 · 2023: 1
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Advanced Biology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, cc-by)
- PubMed Central (acceptedVersion, cc-by)
- IRIS (submittedVersion, cc-by)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- Korea Health Industry Development Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TNIK, immune checkpoint inhibitors, PD-1, CD8+ T cells, tumor-infiltrating T cells, immunogenic cell death, colorectal cancer, immunotherapy sensitization, kinase inhibitors, tumor immune microenvironment
- MeSH terms
- Animals, Disease Models, Animal, Immunotherapy, Colorectal Neoplasms, CD8-Positive T-Lymphocytes, Protein Kinase Inhibitors, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TNIK Inhibition Has Dual Synergistic Effects on Tumor and Associated Immune Cells. https://app.cochat.ai/papers/10.1002/adbi.202200030
- The paper
- Kim, J., Oh, J., Peterson, H. M., Carlson, J. C. T., Pittet, M. J., & Weissleder, R. (2022). TNIK Inhibition Has Dual Synergistic Effects on Tumor and Associated Immune Cells. Advanced Biology. https://doi.org/10.1002/adbi.202200030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.